This series of three webinars, hosted jointly by EATG and AVAC, was designed to prepare and update EATG members for a special meeting on new developments in prevention January 2016 in Brussels. The first webinar addressed the latest updates on PrEP in Europe. Speakers: Dr Valentina Cambiano of University College London, Daniela Rojas Castro of AIDES and Dr Anastasia Pharris of the European Centre for Disease Prevention and Control (ECDC).
EATG 2015 Webinar 1: An update on PrEP in Europe
Global Investment in HIV Cure Research and Development 2014
Now in its third year, this annual report, a collaboration between AVAC and the International AIDS Society Towards a Cure Initiative, analyzes global investment in HIV cure research.
A Pipeline of Promise: Global Health Research and Product Development Process
Global Health Technologies presents an infographic overview of the many steps it takes to bring a product to market.
Post IAS 2015 Webinar: What was presented and what it means on the road to Durban 2016
Advocates and researchers discussed data presented at IAS 2015, its implications and what’s next on the road to Durban 2016!
Demanding Clarity on PrEP: Understanding recent data on oral PrEP
This webinar featured Jean-Michel Molina of the French research agency ANRS and Sheena McCormack of the UK Medical Research Council discussing the data from the IPERGAY and PROUD studies, respectively. Both trials evaluated oral TDF/FTC (brand name Truvada) as PrEP in gay men and other men who have sex with men, and both reported high levels of protection against HIV acquisition. PROUD prescribed a daily pill regimen; IPERGAY asked trial participants to follow an “event driven” regimen that involved a sequence of doses before and after sex. IPERGAY participants took an average of four doses per week—comparable to the estimated protective dose required in trials of daily oral PrEP.
Planned, Ongoing and Completed PrEP Evaluation studies (July 2015)
This graphic, appearing in AVAC Report 2014/15: HIV Prevention on the Line, shows the planned, ongoing and completed PrEP evaluation studies as of July 2015.
HIV Prevention Research & Development Funding Trends, 2000-2014: Investing in innovation in an evolving global health and development landscape
This annual accounting of funding for biomedical HIV prevention research tracks trends and identifies gaps in investment. In 2014, the reported funding for HIV prevention R&D decreased by US$10 million from the previous year to a total of US$1.25 billion. While investments toward research in preventive vaccines, PrEP, female condoms and prevention of vertical transmission increased in 2014, investments towards microbicides, treatment as prevention and medical male circumcision decreased.
Overall funding has remained at nearly the same level for approximately a decade. As in past years, the public sector made up the majority of total funding at US$990 million (79 percent), with the US public sector contributing US$868 million (69 percent). European public-sector funding made up US$69 million (five percent), public-sector investment from other countries made up US$52 million (four percent), philanthropic investment was US$200 million (16 percent) and investment from the commercial sector was US$63 million (five percent).
A one-page summary document is also available.
HIV Prevention Research & Development Funding Trends, 2000-2014: Investing in innovation in an evolving global health and development landscape (1-pager)
This annual accounting of funding for biomedical HIV prevention research tracks trends and identifies gaps in investment. In 2014, the reported funding for HIV prevention R&D decreased by US$10 million from the previous year to a total of US$1.25 billion. While investments toward research in preventive vaccines, PrEP, female condoms and prevention of vertical transmission increased in 2014, investments towards microbicides, treatment as prevention and medical male circumcision decreased.
Overall funding has remained at nearly the same level for approximately a decade. As in past years, the public sector made up the majority of total funding at US$990 million (79 percent), with the US public sector contributing US$868 million (69 percent). European public-sector funding made up US$69 million (five percent), public-sector investment from other countries made up US$52 million (four percent), philanthropic investment was US$200 million (16 percent) and investment from the commercial sector was US$63 million (five percent).
Px Wire July-September 2015, Vol. 8, No. 3
Px Wire is AVAC’s quarterly update covering the latest in the field of biomedical HIV prevention research, implementation and advocacy.
In this issue, we describe the calls to expand ART access to all who need it, which have been amplified over the two months since the results of the START trial. We also document a growing demand for PrEP and the need for updated guidance from the WHO and targets from UNAIDS. And we look at the increasing role civil society is playing at developing PEPFAR Country Operating Plans (COPs) which guide targets, geography, interventions and budget levels on an annual basis.
In our centerspread, we look backwards and forward, at the conferences that took place in Vancouver and Durban in 1996 and 2000 and will again this year and the next.
This issue is also available as a webpage.
Vaccine Research: An overview
This graphic shows the big picture of AIDS vaccine concepts and clinical trials in process and on the horizon. It is an internationally simplified representation of a complex field. Some approaches are not listed, and related arenas like and cure research are omitted.